Key result
Brusatol alters cisplatin pharmacokinetics and nephrotoxicity in mice compared to cisplatin alone.
This is a correction article fixing a missing figure caption regarding the pharmacokinetics of cisplatin and brusatol in mice.
Requires clinical caution for brusatol-cisplatin coadministration; leaves open human relevance of murine PK and nephrotoxicity data.
Correction on: Guo N, Zhang Y, Yuan G, Zhang X, Zhang W and Wen Q (2026) Pharmacokinetics and nephrotoxicity of cisplatin modulated by combination therapy with brusatol. Front. Pharmacol. 17 The original version of this article has been updated.Reminder: Figures, tables, and images will be published under a Creative Commons CC-BY license and permission must be obtained for use of copyrighted material from other sources (including republished/adapted/modified/partial figures and images from the internet). It is the responsibility of the authors to acquire the licenses, to follow any citation instructions requested by third-party rights holders, and cover any supplementary charges.
No takes yet. Share an insight, caveat, or question.
Guo et al. (2026) studied Mice receiving cisplatin with or without brusatol treatment (n=5). Brusatol vs. No brusatol was evaluated on Mean concentration-time curves of cisplatin in plasma, kidneys, and lungs after intraperitoneal injection. Combination therapy with brusatol altered the pharmacokinetics and nephrotoxicity of cisplatin in mice, as shown by modified concentration-time curves in plasma, kidneys, and lungs.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: